Benzimidazoles: An ideal privileged drug scaffold for the design of multitargeted anti-inflammatory ligands

Mini-Reviews in Medicinal Chemistry

Volumn 14, Issue 9, 2014, Pages 747-767

  Kaur, Gaganpreet ^a   Kaur, Maninder ^a   Silakari, Om ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

Anti inflammatory drug targets; Inflammation; Multi factorial; Multi target ligand; Privileged scaffold

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; BENZIMIDAZOLE DERIVATIVE; BLOOD CLOTTING FACTOR 10A; CANNABINOID 2 RECEPTOR AGONIST; CASPASE; CYCLOOXYGENASE 2; CYTOSOLIC PHOSPHOLIPASE A2; GELATINASE A; HISTAMINE H4 RECEPTOR; HISTONE DEACETYLASE; I KAPPA B KINASE EPSILON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; LIGAND; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE KINASE 5; MOLECULAR SCAFFOLD; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHODIESTERASE IV; PROSTAGLANDIN E SYNTHASE 1; STRESS ACTIVATED PROTEIN KINASE; SULINDAC; THROMBIN; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; ANTIINFLAMMATORY AGENT; ENZYME; ENZYME INHIBITOR;

AMINO ACID SUBSTITUTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; DRUG BINDING SITE; DRUG DESIGN; DRUG SCREENING; DRUG TARGETING; ENZYME INHIBITION; HUMAN; IC50; INFLAMMATION; INTRACELLULAR SIGNALING; MOLECULAR DOCKING; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR BINDING ASSAY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; ANIMAL; CHEMISTRY; ENZYMOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SYNTHESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BENZIMIDAZOLES; DRUG DESIGN; ENZYME INHIBITORS; ENZYMES; HUMANS; INFLAMMATION; LIGANDS; MOLECULAR TARGETED THERAPY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84911486576     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557514666140820120518     Document Type: Article

References (75)

1. Libby, P. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr. Rev., 2007, 65, S140-S146.
2. Ribardo, D. A.; Peterson, J. W.; Chopra, A. K. Phospholipase A2-activating protein--an important regulatory molecule in modulating cyclooxygenase-2 and tumor necrosis factor production during inflammation. Indian J. Exp. Biol., 2002, 40, 129-138.
3. Ospina, L. F.; Aragón D. M.; Vergel, N. E.; Isalam, G.; Peŕez, J. E. Anti-inflammatory and antioxidant activities of Phenaxrugosus (Poir.)Wedd and Tabebuiachrysanta G. Nicholson. Vitae, 2011, 18, 49-55.
4. Levin J. I.; Laufer, S. Anti-Inflammatory Drug Discovery. Royal Society of Chemistry: United Kingdom, 2012, 1-4.
5. Dong, X.; Foteinou, P. T.; Calvano, S. E.; Lowry, S. F.; Androulakis, H. P. Agent-based modeling of endotoxin-induced acute inflammatory response in human blood leukocytes. PLoSOne, 2010, 5, e9249.
6. Ashley, N. T.; Weil, Z. M.; Nelson, R. J. Inflammation: Mechanisms, Costs, and Natural Variation. Annu. Rev. Ecol. Evol. Syst., 2012, 43, 385-406.
7. Iwalewa, E. O.; McGaw, L. J.; Naidoo, V.; Eloff, J. N. Inflammation: the foundation of diseases and disorders. A review of phytomedicines of South Africanorigin used to treat pain and inflammatory conditions. Afr. J. Biotechnol., 2007, 6, 2868-2885.
8. Scrivo, R.; Vasile, M.; Bartosiewicz, I.; Valesini, G. Inflammation as "common soil" of the multifactorial diseases. Autoimmun. Rev., 2010, 10, 369-374.
9. Medzhitov, R. Inflammation 2010: new adventures of an old flame. Cell, 2010, 140, 771-776.
10. Loza, M. J.; McCall, C. E.; Li, L.; Isaacs, W. B.; Xu, J.; Chang, B. L. Assembly of inflammation-related genes for pathway-focused genetic analysis. PLoS One, 2007, 2, e1035.
11. Simmons, D. L. What makes a good anti-inflammatory drug target? Drug Discov. Today, 2006, 11, 210-219.
12. Ward, S. G. New drug targets in inflammation: efforts to expand the anti-inflammatory armoury. Br. J. Pharmacol., 2008, 53, S5-S6.
13. Bennamane, N.; Nedjar-Kolli, B.; Geronikaki, A. A.; Eleftheriou, P. T.; Kaoua, R.; Boubekeur, K.; Hoffman, P.; Chaudhary, S. S.; Saxena, A. K. N-Substituted phenyl-pyrazolo-oxazin-2-thiones as cox-lox inhibitors: Influence of the replacement of the oxo-group with thioxo-group on the cox Inhibition activity of n-substituted pyrazolo-oxazin-2-ones. ARKIVOC, 2011, 2, 69-82.
14. Yang, K.; Bai, H.; Ouyang, Q.; Lai, L.; Tang, C. Finding multiple target optimal intervention in disease-related molecular network. Mol Syst. Biol., 2008, 4, 1-13. DOI: 10. 1038/msb. 2008. 60.
15. Bottegoni, G.; Favia, A. D.; Recanatini, M.; Cavalli, A. The role of fragment-based and computational methods in polypharmacology. Drug Discov. Today, 2011, 17, 23-34.
16. Mizuno, C. S.; Chittiboyina, A. G.; Shah, F. H.; Patny, A.; Kurtz, T. W.; Pershadsingh, H. A.; Speth, R. C.; Karamyan, V. T.; Carvalho, P. B.; Avery, M. A. Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome. J. Med. Chem., 2010, 53, 1076-1085.
17. Neves, G.; Menegatti, R.; Antonio, C. B.; Grazziottin, L. R.; Vieira, R. O.; Rates, S. M. K.; Noël, F.; Barreiro, E. J.; Fraga, C. A. M. Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HTxa receptors. Bioorg. Med. Chem., 2010, 18, 1925-1935.
18. Ezerzer, C.; Dolgin, M.; Skovorodnikova, J.; Harris, N. Chemokine receptor-derived peptides as multi-target drug leads for the treatment of inflammatory diseases. Peptides, 2009, 30, 1296-1305.
19. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today, 2004, 9, 641-651.
20. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem., 2005, 48, 6523-6543.
21. Korcsmáros, T.; Szalay, M. S.; Böde, C.; Kovács, I. A.; Csermely, P. How to design multi-target drugs: Target-search options in cellular networks. Expert Opin. Drug Discov., 2007, 2, 1-10.
22. Horton, D. A.; Bourne, G. T.; Smythe, M. L. The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem. Rev., 2003, 103, 893-930.
23. Bongarzone, S.; Bolognesi, M. L. The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases. Expert Opin. Drug Discov., 2011, 6, 251-268.
24. Poupaert, J.; Carato, P.; Colacino, E. 2(3H)-benzoxazolone and bioisosters as "privileged scaffold" in the design of pharmacological probes. Curr. Med. Chem., 2005, 12, 877-885.
25. Klekota, J.; Roth, F. P. Chemical substructures that enrich for biological activity. Bioinformatics, 2008, 24, 2518-2525.
26. Schnur, D. M.; Hermsmeier, M. A.; Tebben, A. J. Are target-family-privileged substructures truly privileged? J. Med. Chem., 2006, 49, 2000-2009.
27. Welsch, M. E.; Snyder, S. A.; Stockwell, B. R. Privileged scaffolds for library design and drug discovery. Curr. Opin. Chem. Biol., 2010, 14, 347-361.
28. Bemis, G. W.; Murcko, M. A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem., 1996, 39, 2887-2893.
29. Wright, J. B. The chemistry of the benzimidazoles. Chem. Rev., 1951, 48, 397-541.
30. Adler, T. K. Albert, A. The biological and physical properties of the azaindoles. J. Med. Chem., 1963, 6, 480-483.
31. Vourloumis, D.; Takahashi, M.; Simonsen, K. B.; Ayida, B. K.; Barluenga, S.; Winters, G. C.; Hermann, T. Solid-phase synthesis of benzimidazole libraries biased for RNA targets. Tetrahedron Lett., 2002, 44, 2807-2811.
32. Townsend, L. B.; Revankar, G. R. Benzimidazole nucleosides, nucleotides, and related derivatives. Chem. Rev., 1970, 70, 389-438.
33. Infante-Castillo, R.; Hernández-Rivera, S. P. Experimental and theoretical studies of the molecular structure of 1-(2-pyridinylmethyl)-2-methylbenzimidazole. J. Mol. Struct., 2010, 968, 6-12.
34. Spasov, A. A.; Yozhitsa, I. N.; Bugaeva, L. I.; Anisimova, V. A. Benzimidazole derivatives: Spectrum of pharmacological activity and toxicological properties (a review). Pharm. Chem. J., 1999, 33, 232-243.
35. Bansal, Y.; Silakari, O. The therapeutic journey of benzimidazoles: a review. Bioorg. Med. Chem., 2012, 20, 6208-6236.
36. Kuldipsinh, P. B.; Stoyanka, N.; Illiyan, I.; Manjunath, D. G. Novel research strategies of benzimidazole derivatives: a review. Mini Rev. Med. Chem., 2013, 13, 1421-1447.
37. Secci, D.; Bolasco, A.; D'Ascenzio, Mdella Sala, F.; Yáñez, M.; Carradori, S. Conventional and microwave-assisted synthesis of benzimidazole derivatives and their in vitro inhibition of human cyclooxygenase. J. Heterocycl. Chem., 2012, 49, 1187-1195.
38. Gaba, M.; Singh, D.; Singh, S.; Sharma, V.; Gaba, P. Synthesis and pharmacological evaluation of novel 5-substituted-1-(phenylsulfonyl)-2-methylbenzimidazole derivatives as antiinflammatory and analgesic agents. Eur. J. Med. Chem., 2010, 45, 2245-2249.
39. Michaux, C.; de Leval, X.; Julémont, F.; Dogné, J. M.; Pirotte, B.; Durant, F. Structure-based pharmacophore of COX-2 selective inhibitors and identification of original lead compounds from 3D database searching method. Eur. J. Med. Chem., 2006, 41, 1446-1455.
40. Nakano, H.; Inoue, T.; Kawasaki, N.; Miyataka, H.; Matsumoto, H.; Taguchi, T.; Inagaki, N.; Nagai, H.; Satoh, T. Synthesis of benzimidazole derivatives as antiallergic agents with 5-lipoxygenase inhibiting action. Chem. Pharm. Bull., 1999, 47, 1573-1578.
41. Nakano, H.; Inoue, T.; Kawasaki, N.; Miyataka, H.; Matsumoto, G.; Taguchi, T.; Inagaki, N.; Nagai, H.; Satoh, T. Synthesis and biological activities of novel antiallergic agents with 5-lipoxygenase inhibiting action. Bioorg. Med. Chem., 2000, 8, 373-380.
42. Bovens, S.; Kaptur, M.; Schulze Elfringhoff, A.; Lehr, M. 1-(5-Carboxyindol-1-yl)propan-2-ones as inhibitors of human cytosolic phospholipase A2alpha: synthesis and properties of bioisosteric-benzimidazole, benzotriazole and indazole analogues. Bioorg. Med. Chem. Lett., 2009, 19, 2107-2111.
43. Regan, J.; Bruno, J.; McGarry, D.; Poli, G.; Hanney, B.; Bower, S.; Travis, J.; Sweeney, D.; Miller, B.; Souness, J.; Djuric, S. 2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors. Bioorg. Med. Chem. Lett., 1998, 8, 2737-2742.
44. Chu, L.; Ogawa, A.; Ok, H. O.; Ujjainwalla, F. Benzimidazoleandaza-benzimidazolecarboxamides. U. S. Patent 0207750 A1, August 25, 2011.
45. Hamley, P.; Tinker, A. C. 1, 2-Diaminobenzimidazoles: selective inhibitors of nitric oxide synthase derived from aminoguanidine. Bioorg. Med. Chem. Lett., 1995, 5, 1573-1576.
46. Kita, Y.; Muramoto, M.; Fujikawa, A.; Yamazaki, T.; Notsu, Y.; Nishimura, S. Discovery of novel inhibitors of inducible nitric oxide synthase. J. Pharm. Pharmacol., 2002, 54, 1141-1145.
47. Pfau, R.; Arndt, K.; Doods, H.; Hauel, N.; Klinder, K.; Kuelzer, R.; Mack, J.; Stenkamp, D. 1H-Benzimidazole-5-carboxamides as antiinflammatory agents. U. S. Patent 0122930 A1, May 17, 2012.
48. Banoglu, E.; Çalişkan, B.; Luderer, S.; Eren, G.; Özkan, Y.; Altenhofen, W.; Weinigel, C.; Barz, D.; Gerstmeier, J.; Pergola, C.; Werz, O. Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP). Bioorg. Med. Chem., 2011, 20, 3728-3741.
49. Roufett, M.; de Oliveira, C. A. F.; Udi, Y.; Agrawal, A.; Sagi, I.; McCammon, J. A.; Cohen, S. M. From sensors to silencers: Quinoline-and Benzimidazole-Sulfonamides as inhibitors for zinc proteases. J. Am. Chem. Soc., 2010, 132, 8232-8233.
50. Bressi, J. C.; de Jong, R.; Wu, Y.; Jennings, A. J.; Brown, J. W.; O'Connell, S.; Tari, L. W.; Skene, R. J.; Vu, P.; Navre, M.; Cao, X.; Gangloff, A. R. Benzimidazole and imidazole inhibitors of histone deacetylases: Synthesis and biological activity. Bioorg. Med. Chem. Lett., 2010, 20, 3138-3141.
51. Connor, D. T.; Glase, S. A.; Purchase, T. S.; Roth, B. D.; Trivedi, A. K. 2-Phenyl benzimidazole derivatives as MCP-1 antagonists. U. S. Patent 6, 348, 487 B1, February 19, 2002.
52. Kay, D.; Golec, J. M. C. Imidazole and benzimidazolecaspase inhibitors and uses thereof. U. S. Patent 205, 327 B2, April 17, 2007.
53. Okolotowicz, K. J.; Shi, R.; Zheng, X.; MacDonald, M.; Reed, J. C.; Cashman, J. R. Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway. Bioorg. Med. Chem., 2010, 18, 1918-1924.
54. Liu, G.; Huth, J. R.; Olejniczak, E. T.; Mendoza, R.; DeVeries, P.; Leitza, S.; Reilly, E. B.; Okasinski, G. F.; Fesik, S. W.; von Geldern, T. W. Novel p-arylthiocinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties. J. Med. Chem., 2001, 44, 1202-1210.
55. Verbist, B. M. P.; De Cleyn, M. A. J.; Surkyn, M.; Fraiponts, E.; Aerssens, J.; Nijsen, M. J. M. A.; Gijsen, H. J. M. 5-Sulfonyl-benzimidazoles as selective CB2 agonists. Bioorg. Med. Chem. Lett., 2008, 18, 2574-2579.
56. Goebel, M.; Wolber, G.; Markt, P.; Staels, B.; Unger, T.; Kintscher, U.; Gust, R. Characterization of new PPARgamma agonists: benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode. Bioorg. Med. Chem. 2010, 18, 5885-5895.
57. Venable J. D.; Cai, H.; Chai, W.; Dvorak, C. A.; Grice, C. A.; Jablonowski, J. A.; Shah, C. R.; Kwok, A. K.; Ly, K. S.; Pio, B.; Wei, J.; Desai, P. J.; Jiang, W.; Nguyen, S.; Ling, P.; Wilson, S. J.; Dunford, P. J.; Thurmond, R. L.; Lovenberg, T. W.; Karlsson, L.; Carruthers, N. I.; Edwards, J. P. Preparation and biological evaluation of indole, benzimidazole, and thienopyrrolepiperazinecarboxamides: potent human histamine H4 antagonists. J. Med. Chem., 2005, 48, 8289-8298.
58. Flaherty, P. T.; Chopra, I.; Jain, P.; Yi, S.; Allen, E.; Cavanaugh, C. Identification of benzimidazole-based inhibitors of the mitogen activated kinase-5 signaling pathway. Bioorg. Med. Chem. Lett., 2010, 20, 2892-2896.
59. Takeuchi, K.; Bastian, J. A.; Gifford-Moore, D. S.; Harper, R. W.; Miller, S. J.; Mullaney, J. T.; Sall, D. J.; Smith, G. F.; Zhang, M.; Fisher, M. J. 1, 2-Disubstituted indole, azaindole and benzimidazole derivatives possessing amine moiety: a novel series of thrombin inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 2347-2351.
60. Zhao, Z.; Arnaiz, D. O.; Greidel, B.; Sakata, S.; Dallas, J. L.; Whitlow, M.; Trinh, L.; Post, J.; Liang, A.; Morrissey, M. M.; Shaw, K. J. Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 963-966.
61. Powers, J. P.; Li, S.; Jaen, J. C.; Liu, J.; Walker, N. P. C.; Wang, Z.; Wesche, H. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg. Med. Chem. Lett., 2006, 16, 2842-2845.
62. de Dios, A.; Shih, C.; López de Uralde, B.; Sánchez, C.; del Prado, M.; Martín Cabrejas, L. M.; Pleite, S.; Blanco-Urgoiti, J.; Lorite, M. J.; Nevill, C. R.; Bonjouklian, R.; York, J.; Vieth, M.; Wang, Y.; Magnus, N.; Campbell, R. M.; Anderson, B. D.; McCann, D. J.; Giera, D. D.; Lee, P. A.; Schultz, R. M.; Li, L. C.; Johnson, L. M.; Wolos, J. A. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy. J. Med. Chem., 2005, 48, 2270-2273.
63. Bamborough, P.; Christopher, J. A.; Cutler, G. J.; Dickson, M. C.; Mellor, G. W.; Morey, J. V.; Patel, C. B.; Shewchuk, L. M. 5-(1H-Benzimidazol-1-yl)-3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK-epsilon kinase. Bioorg. Med. Chem. Lett., 2006, 16, 6236-6240.
64. Kaur, M.; Bahia, M. S.; Silakari, O. Inhibitors of interleukin-2 inducible T-cell kinase as potential therapeutic candidates for the treatment of various inflammatory disease conditions. Eur. J. Pharm. Sci., 2012, 47, 574-588.
65. Teague, S. J.; Barber, S.; King, S.; Stein, L. Synthesis of benzimidazole based JNK inhibitors. Tetrahedron Lett., 2005, 46, 4613-4616.
66. Cole, A. G.; Bohnstedt, A. C.; Paradkar, V.; Kingsbury, C.; Quintero, J. G.; Park, H.; Lu, Y.; You, M.; Neagu, I.; Diller, D. J.; Letourneau, J. J.; Shao, Y.; James, R. A.; Riviello, C. M.; Ho, K. K.; Lin, T. H.; Wang, B.; Appell, K. C.; Sills, M.; Quadros, E.; Kimble, E. F.; Ohlmeyer, M. H.; Webb, M. L. 2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 6788-6792.
67. Murray, J. M.; Sweeney, Z. K.; Chan, B. K.; Balazs, M.; Bradley, E.; Castanedo, G.; Chabot, C.; Chantry, D.; Flagella, M.; Goldstein, C. M.; Kondru, R.; Lesnick, J.; Li, J.; Lucas, M. C.; Nonomiya, J.; Pang, J.; Price, S.; Salphati, L.; Safina, B.; Savy, P. P.; Seward, D. M.; Ultsch, M.; Sutherlin, D. P. Potent and highly selective benzimidazole inhibitors of PI3-kinase delta. J. Med. Chem., 2012, 55, 7686-7695.
68. Sabat, M.; VanRens, J. C.; Laufersweiler, M. J.; Brugel, T. A.; Maier, J.; Golebiowski, A.; De, B.; Easwaran, V.; Hsieh, L. C.; Walter, R. L.; Mekel, M. J.; Evdokimov, A.; Janusz, M. J. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck). Bioorg. Med. Chem. Lett., 2006, 16, 5973-5977.
69. Zhang, G.; Ren, P.; Gray, N. S.; Sim, T.; Liu, Y.; Wang, X.; Che, J.; Tian, S. S.; Sandberg, M. L.; Spalding, T. A.; Romeo, R.; Iskandar, M.; Chow, D.; Martin Seidel, H.; Karanewsky, D. S.; He, Y. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I. Bioorg. Med. Chem. Lett., 2008, 18, 5618-5621.
70. Sessions, E. H.; Smolinski, M.; Wang, B.; Frackowiak, B.; Chowdhury, S.; Yin, Y.; Chen, Y. T.; Ruiz, C.; Lin, L.; Pocas, J.; Schröter, T.; Cameron, M. D.; LoGrasso, P.; Feng, Y.; Bannister, T. D. The development of benzimidazoles as selective rho kinase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 1939-1943.
71. Nakane, M.; Stevens, R. W. Benzimidazole compounds and their use. U. S. Patent, 5, 141, 950, August 25, 1992.
72. Hwang, S. H.; Wecksler, A. T.; Wagner, K.; Hammock, B. D. Rationally designed multitarget agents against inflammation and pain. Curr. Med. Chem., 2013, 20, 1783-1799.
73. Payne, J. E.; Bonnefous, C.; Symons, K. T.; Nguyen, P. M.; Sablad, M.; Rozenkrants, N.; Zhang, Y.; Wang, L.; Yazdani, N.; Shiau, A. K.; Noble, S. A.; Rix, P.; Rao, T. S.; Hassig, C. A.; Smith, N. D. Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4, 5-b]pyrazin-1-yl)methyl)-7, 8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS/nNOS dimerization inhibitors that are orally active in pain models. J. Med. Chem., 2010, 53, 7739-7755.
74. Singla, P.; Luxami, V.; Paul, K. Benzimidazole-biologically attractive scaffold for protein kinase inhibitors. RSC Adv., 2014, 4, 12422-12440.
75. Garuti, L.; Roberti, M.; Bottegoni, G. Benzimidazole Derivatives as Kinase Inhibitors. Curr. Med. Chem., 2014, 21, 2284-2298.